3,233 Shares of Moderna, Inc. $MRNA Acquired by Pinkerton Wealth LLC

Pinkerton Wealth LLC acquired a new position in Moderna, Inc. (NASDAQ:MRNA) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 3,233 shares of the company’s stock, valued at approximately $623,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of MRNA. BlackRock Inc. bought a new position in Moderna during the 2nd quarter worth approximately $2,142,877,000. Theleme Partners LLP bought a new stake in Moderna in the second quarter valued at approximately $564,272,000. Wellington Management Group LLP lifted its position in Moderna by 4.4% in the second quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock valued at $172,384,000 after purchasing an additional 103,977 shares during the last quarter. First Trust Advisors LP lifted its position in Moderna by 59.3% in the first quarter. First Trust Advisors LP now owns 2,392,693 shares of the company’s stock valued at $121,549,000 after purchasing an additional 891,072 shares during the last quarter. Finally, Merck & Co. Inc. purchased a new stake in shares of Moderna during the second quarter valued at approximately $161,642,545. Institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on MRNA shares. Royal Bank Of Canada restated a “sector perform” rating and issued a $130.00 target price on shares of Moderna in a report on Wednesday, August 19th. UBS Group reiterated a “neutral” rating on shares of Moderna in a report on Tuesday, September 22nd. Deutsche Bank Aktiengesellschaft began coverage on shares of Moderna in a research report on Friday, August 28th. They set a “hold” rating and a $125.00 price target for the company. Morgan Stanley raised their price target on shares of Moderna from $89.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. Finally, Piper Sandler restated an “overweight” rating and issued a $230.00 price objective (up from $167.00) on shares of Moderna in a research report on Monday, October 26th. Six investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $107.10.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna’s personalized cancer-vaccine candidate remains a key potential catalyst. Recent clinical data have encouraged investors, and Chief Executive Stéphane Bancel defended the melanoma results, saying the data could improve over time and that competitors may not easily replicate the company’s technology. Will Moderna Soar on Nov. 6? Moderna’s CEO discusses its cancer vaccine
• Positive Sentiment: Coverage comparing Moderna with BioNTech highlights the company’s oncology platform and its potential role in the growing mRNA cancer-vaccine market. Successful follow-up data could support Moderna’s long-term growth narrative. Moderna cancer results versus BioNTech
• Neutral Sentiment: Investor attention is elevated ahead of Moderna’s quarterly earnings release. The report may provide updated financial guidance and more information about the company’s pipeline, but heavy searches alone do not change the underlying outlook. Moderna projected to announce quarterly earnings
• Negative Sentiment: Analysts expect Moderna’s third-quarter earnings to decline, and Zacks says the company lacks the combination of factors typically associated with a likely earnings beat. That is weighing on expectations ahead of the report. Moderna Q3 earnings preview
• Negative Sentiment: William Blair lowered Moderna to Market Perform, while an analyst also reduced the company’s fiscal 2028 EPS estimate. The actions reinforce concerns about the premium valuation, limited near-term earnings visibility and the time required for oncology programs to mature. Moderna rating lowered to Market Perform Moderna FY2028 EPS estimate lowered

Insider Buying and Selling at Moderna

In other Moderna news, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the sale, the insider directly owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. The trade was a 4.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jamey Mock sold 34,836 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the transaction, the chief financial officer owned 59,375 shares in the company, valued at $7,985,343.75. This trade represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 197,251 shares of company stock valued at $33,875,904. 10.80% of the stock is currently owned by corporate insiders.

Moderna Stock Performance

Shares of MRNA opened at $221.72 on Monday. The firm’s 50-day moving average price is $182.49 and its 200-day moving average price is $86.52. The firm has a market capitalization of $88.52 billion, a price-to-earnings ratio of -27.75 and a beta of 1.16. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $254.48.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. During the same period in the prior year, the firm earned ($2.13) earnings per share. Moderna’s revenue was up 2.1% on a year-over-year basis. Sell-side analysts anticipate that Moderna, Inc. will post -6.11 EPS for the current year.

Moderna Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.